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Abstract
Diabetes is the most common serious metabolic disorder and one of the five leading 
causes of death worldwide. It is characterized by persistent hyperglycemia coincident 
with the induction of oxidative stress and alterations in glucose and lipid metabolism–
regulating enzymes. Resveratrol has immerged as one of the leading natural ingredients 
to combat diabetic and its complications. Despite an abundance of laboratory and animal 
research, there is little clinical evidence to establish resveratrol effectiveness as a thera-
peutic against diabetes. Further, the poor bioavailability and stability of resveratrol in 
humans have been a major concern for translating basic science findings into clinical 
utility. In this review, we embark on large, well-controlled clinical studies to confirm the 
efficacy of resveratrol in the management of diabetes mellitus and gain a better insight 
into its biological effects in humans. Further possible methods of increasing the stability 
and bioavailability for such trials are also discussed.
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1. Introduction
Diabetes mellitus (DM) has been an ever-increasing global epidemic and one of the most chal-
lenging health problems of twenty-first century. In 2010, more than 285 million people about 
the world were afflicted with diabetes, and it was then calculated that the number of people 
with diabetes will increase to 439 million by 2030. Interestingly, the reports of 2015 show that 
globally 415 million (215.2 million men and 199.5 million women) had DM with a prevalence 
of 8.8%, and projections indicate that approximately 600 million people would be suffering 
from diabetic in 2030. In other words, one in eleven people has DM. The economic impact 
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of diabetes is extensive. A significant component of health care expenditures is attributed to 
diabetes, and its complications and global spending for treating it in 2015 alone were US$ 673 
billion (12% of health expenditure) [1].
Two primary groups of DM are distinguished: (1) autoimmune T1DM or insulin-dependent 
DM or juvenile DM and (2) T2DM or noninsulin-dependent DM or maturity onset DM. Close 
to 90% of people with DM around the world have type 2 DM (T2DM) [2].
The treatment of T1DM requires insulin replacement via injections as the pancreatic β-cells 
are destroyed and do not secrete adequate insulin. On the other hand, T2DM is characterized 
by insulin resistance and a decreased capacity of insulin secretion by β-cells. Natural/herbal 
medicines that have claimed to be effectual in the treatment of DM are thus more efficient in 
the treatment of T2DM [3]. They act either as insulin sensitizers or as substances that reduce 
the plasma glucose levels.
Further recent inventions on natural products have established a new understanding into 
the use of antioxidants to combat diabetic complications [4]. Oxidative stress leads to the 
dysfunction of β-cells and thus plays a crucial role in the pathogenesis of diabetes and its 
associated complications. In fact, increasing morbidity and mortality rates of T2DM patients 
are mainly due to the high occurrence and severity of diabetic complications.
Thus, β-cells apoptosis can be protected, and their functions can be preserved by the use of 
antioxidants [5]. Thus, a potent antioxidant compound is expected to show greater effects 
on diabetes and its associated complications. Therefore, antioxidant therapy is, a different, 
innovative but, a fundamental approach for treating diabetic complications [6, 7].
The antioxidant activity and its related health benefits of dietary plant polyphenols are well 
documented. In recent years, there is growing evidence on the effectiveness of plant polyphe-
nols against the treatment of type 2 diabetes mellitus and its ramifications. Polyphenols may 
be classified into different groups as a function of the number of phenol rings that they contain 
and on the basis of structural elements that bind these rings to one another. The main classes 
include flavonoids, phenolic acids, β-orcinols, stilbenes, and lignans. Figure 1 illustrates the 
different groups of polyphenols and their chemical structures reported as antioxidant and 
antidiabetic activities.
The hypoglycemic effects of polyphenols are mainly ascribed for reducing the intestinal 
absorption of dietary carbohydrate, for the modulation of carbohydrate and lipid metabolism 
enzymes, and they stimulate insulin secretion and insulin action and improve β-cell func-
tions by reducing oxidative stress, stress-sensitive signaling pathways, and inflammatory 
processes [8].
We have already reviewed the antidiabetic effect of least-studied β-orcinol compounds of 
lichen origin and found in accordance of its antioxidant and antidiabetic effect [9]. The current 
chapter focuses on the reported antidiabetic effect of stilbenoid type polyphenols. Stilbenoids 
are phylotaxins and are mainly found in Vitis vinifera L., the wine producing grape fruits, 
together with other plant families, such as Dipterocarpaceae, Gnetaceae, and Fabaceae.
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The backbone structure of stilbene which is 1,2-diphenylethylene is common, but the type and 
position of substituents on the rings differ. The hydroxylated derivatives of stilbenes provide 
the class with a wide variety of polymerization and oligomeric construction. However, the 
most widely studied hydroxylated stilbenoid is resveratrol (3,5,4′-trihydroxystilbene), which 
is considered as one of most potent natural biological active compound. The other structural 
analogs with potentially beneficial medicinal properties include pterostilbene (methylated 
derivatives), viniferin (glycone derivatives), and hopeaphenol (oligomeric forms—tetramer). 
Some of the common stilbenoid structures are illustrated in Figure 2.
Biological activities of resveratrol have been well examined by a great variety of test systems. 
Its beneficial properties on humans include neuroprotective, antiviral, antiatherogenic, and 
estrogen-like growth-promoting effect. Further, its effects on promotion of vasodilatation 
and prevention of platelet aggregation and its positive effect on the circulatory system espe-
cially by increasing production of high-density lipoprotein cholesterol and preventing the 
development of arteriosclerosis are reported. Furthermore, it was shown that resveratrol 
is a chemopreventive agent [10]. Due to the wide variety of biological activities shown by 
this marvel compound, resveratrol-based medicinal chemistry has become rapidly evolv-
ing and increasingly active topics in the past decade, covering almost the whole range of 
therapeutic fields. There are several reports composing the antioxidant, antiinflammatory, 
and antidiabetic effect of resveratrol. Due to its antiinflammatory and antioxidant effects, 
resveratrol can mitigate the development of diabetic complications associated with inflam-
mation and oxidative stress. Beneficial effects of resveratrol on the management of blood 
glucose in diabetes are summarized in Figure 3. The aim of this chapter is to highlight the 
importance of resveratrol along with other stilbenes as an antidiabetic compound with anti-
oxidant properties.
Figure 1. Chemical structure of major classes of polyphenols reported for antioxidant and antidiabetic effects.
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2. The role RSV in obesity and diabetes and its molecular 
mechanism
The appreciable magnitude of scientific evidence is available, which ascribes antidiabetic 
properties of resveratrol and fights against obesity. There are over 800 publications ascribing 
Figure 2. Most common stilbene derivatives reported for antidiabetic activities.
Figure 3. Beneficial effects of resveratrol on the management of blood glucose in diabetes.
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the hypoglycemic action of resveratrol, through both in-vivo and in-vitro studies. Multiple 
modes of action, and diversity of molecular targets, keep resveratrol well ahead of its other 
natural analogs. Modes of action include inhibition of carbohydrate hydrolyzing enzymes 
(α-amylase and α-glucosidase), through their role as an effective antioxidants and through 
their effect on amelioration of insulin sensitivity. The resveratrol improves defective insulin 
signaling, prevents pancreatic β-cell apotopsis and dysfunction, inhibits abnormal glucose 
uptake and storage, mitigates hyperlipidemia and dyslipidemia, and thus shows high phar-
mokinetic potential as antidiabetic agent [11]. The complex physiological action of resveratrol 
as an antidiabetic agent could be attributed to its capacity to modulate different pathways and 
to its diversity of molecular targets including phospodiesterases, adenylyl cyclase, kinases, 
sirtuins, transcription factors, cytokines, and others, some of which are described below.
Pancreatic β-cells are key players in the development of T2DM, as they are required to 
secrete increasing amounts of insulin so as to compensate for increasing insulin resistance. 
Consequently, the β-cells come under increasing metabolic stress and finally their function 
deteriorates. Thus, it is important to find a mean to preserve the health of β-cells.
Cyclic nucleotide phosphodiesterases (PDEs) belong to a class of enzymes that hydrolyze the 
phosphodiester bonds of cAMP and cGMP to their biologically inactive 5′ derivatives. Cyclic 
AMP is known as a key mediator of metabolic regulation. Resveratrol acts as PDE inhibitor, 
leading to increased cAMP levels, which amplifies glucose-induced insulin secretion [12].
Resveratrol triggers cascade of biological pathways that are induced during calorie restriction. 
Primarily increased cAMP levels activate PKA (protein kinase A), which directly phosphory-
lates and activates histone deacetylase Sirtuin1 (SIRT1), which increases insulin sensitivity and 
protects against metabolic damage resulting from a high-fat diet. In detail, SIRT1 catalyzes 
NAD+-dependent protein deacetylation, yielding nicotinamide and O-acetyl-ADP-ribose. 
SIRT1 facilitates the conversion of changes in the nutritional status, which it senses via NAD+ 
levels, mediates the metabolic stress situations, such as high-fat-diet-induced obesity, and 
plays a context-dependent role in health span regulation. In addition to the c-AMP mediated 
pathway, resveratrol also increases SIRT1 activity through an allosteric interaction, resulting 
in the increase of SIRT1 affinity for both NAD+ and the acetylated substrate. SIRT1 promotes 
many beneficial metabolic changes, such as an increase in fatty acid oxidation, gluconeogen-
esis, and mitochondrial respiration and a decrease in triglyceride synthesis, glycolysis, ROS 
production, and inflammation. In light of the rising number of patients suffering from meta-
bolic diseases, compounds that activate SIRT1 directly or indirectly offer protection against 
the onset of metabolic damage and encourage healthy aging [13].
The regulation of glucose uptake and its subsequent utilization is critical for the maintenance 
of glucose homeostasis. Homeostasis of blood glucose by insulin involves stimulation of 
glucose uptake by translocation of glucose transporter Glut-4 from intracellular pool to the 
caveolar membrane system. Resveratrol increases the expression of this glucose transporter 
Glu-4 and excites the glucose uptake.
Skeletal muscle is the largest organ in the body and contributes to immeasurable features of 
organismal biology, and its dysfunction stimulates numerous diseases, including diabetes. 
Skeletal muscle is the main site of glucose disposal after glucose ingestion. Insulin resistance 
in skeletal muscle is thus the main driver of postprandial hyperglycemia. The transcriptional 
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coactivator PGC-1α has emerged as a key driver of metabolic programming in skeletal muscle, 
both in muscle health and disease. PGC-1α has different roles in different tissues, but in nearly 
every context, PGC-1α stimulates the transcriptional program of mitochondrial biogenesis. 
PGC-1α dysfunction, and thus mitochondrial insufficiency, contributes to insulin resistance in 
skeletal muscle. Resveratrol also has proven to enhance the PGC-1α–skeletal muscle protein 
levels.
Further resveratrol also activates Akt expression, a modulator of insulin-signaling pathway. 
Akt is the major effector of the IR-IRS-1-PI3K pathway and is activated by phosphorylation. 
Resveratrol treatment increases the phosphorylation level of Akt, particularly of its Thr308 
and Ser473 residues which is essential for its basal and full activation.
Several studies have found that resveratrol has positive effects on inhibiting the insulin secre-
tion from pancreatic β-cells and prevents it from chronic overstimulation, decreases the plasm 
insulin concentration, and increases the insulin sensitivity. Possible explanations include res-
veratrol-mediated suppression of cytokine action through decreased DNA binding of nuclear 
transcription factor κB, production of nitric oxide, and expression of inducible nitric oxide 
synthesis [14].
2.1. Antioxidant effect of RSV
The advancement in the knowledge of potent antioxidants has uncovered the way for greater 
insight in the treatment of diabetic complications. The antioxidant activity of resveratrol is 
well proven, and there is a good accordance between antioxidant and antidiabetic activity of 
resveratrol. Resveratrol maintains the concentration of intracellular antioxidants in biological 
systems by dual methods, that is, by acting as scavenger of free radicals and by increasing 
the activity of antioxidant enzymes such as catalase, glutathione peroxidase, glutathione 
S-transferase, and glutathione reductase [14]. In a study on isolated liver mitochondria, addi-
tion of resveratrol to the incubation medium significantly increased the activity of manga-
nese-containing superoxide dismutase and diminishes ROS generation. Resveratrol acts as a 
free radical scavenger of ROS and reactive nitrogen species such as superoxide anion (O2•−), 
hydroxyl radical (OH•), and hydrogen peroxide, thus, prevent DNA lesions and lipid per-
oxidation in cell membranes. It has been shown that resveratrol significantly reduced the 
oxidation of thiol groups in proteins of human platelets [15].
2.2. Effect of RSV on carbohydrate metabolism, through its α-amylase and 
α-glucosidase inhibitory activities
α-Amylase and α-glucosidase are key enzymes involved in carbohydrate digestion. α-Amylase 
hydrolyzes starch and glycogen into maltose and ultimately increases the blood sugar. 
α-Glucosidase hydrolyzes oligosaccharides and disaccharides into glucose, which is absorbed 
through the gut wall to become blood glucose. Thus, inhibition of the activity of these enzymes 
is viewed as one of the most effective therapeutic approaches in the reduction of glucose levels 
in plasma, as a consequence, the suppression of postprandial hyperglycemia.
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Various plant extracts containing resveratrol have been evaluated for α-amylase inhibi-
tory activity and have shown beneficial effects in bringing down the pace of digestion and 
assimilation of sugars and thereby leading to the effective management of type 2 diabetes by 
decreasing the postprandial hyperglycemia, some of which are highlighted below.
Antioxidant and α-glucosidase inhibitory potential of reservatrol isolated from Rumex buceph-
alophorus have been reported, which revealed that reservatrol was at least five times more 
potent α-glucosidase inhibitory activity as compared to standard drug acarbose [16]. A study 
on peanut extracts correlated the reservatrol content with the α-amylase and α-glucosidase 
inhibitory activity. The EtOAc extracts of peanuts with higher resveratrol content (3 μg/ml) 
showed higher α-amylase and α-glucosidase inhibitory activity (4.32 and 5.93%, respectively) 
as compared to MeOH extract (3.9 and 4.9%) with resveratrol content of (0.5 μg/ml). The 
standard resveratrol sample showed α-amylase and α-glucosidase inhibitory activity (5.18 
and 5.94%) [17].
In another study, resveratrol had shown potent α-glucosidase inhibitory activity against both 
yeast and mammal α-glucosidase with (IC50, 0.091 mg/ml) and (IC50, 0.12 mg/ml), respec-tively. The standard drug acarbose showed IC50 = 0.247 mg/ml (yeast α-glucosidase) and IC50 = 0.013 μg/ml (mammal α-glucosidase) [15]. Piceatannol, with an additional OH group as compared to resveratrol, showed higher α-glucosidase inhibitory activity as compared to 
resveratrol [18].
In a study, wistar rats when administered with 30 mg/kg BW resveratrol 60 min prior to 
sucrose- or starch-loading had a delayed absorption of carbohydrates, resulting in significant 
lowering of postprandial blood glucose concentrations [18].
The structure activity relationship of polyphenols isolated from other plant sources has 
been extensively reviewed as inhibitors of α-amylase and α-glucosidase. Detailed SAR has 
revealed that both α-amylase and α-glucosidase share the same properties in terms of struc-
tural requirements for inhibition [19]. Studies reveal that inhibitory activity is influenced by 
a number of hydroxyl groups and their positions, methylation, methoxylation, glycosylation, 
etc. Broadly, it is considered that hydroxylation of phenols increases the α-amylase inhibitory 
activity and methoxylation, which blocks the free hydroxyl groups and reduces the inhibitory 
activity [19]. Apparently, the activity is increased by more phenolic substitutions. Piceatannol 
with four OH groups showed higher activity than resveratrol with three free hydroxyl groups 
as for the study of Zhang et al. [18]. This is further evident by the study of Lam et al. [26], 
where several stilbenoids isolated from seeds of Syagrus romanzoffiana were evaluated for 
inhibitory activity against α-glucosidase Bacillus stearothermophilus. Pentahydroxystilbene (5 
OH groups) showed higher inhibitory activity (IC50 19.23 μM) as compared to piceatannol with 4 OH groups (IC50 23.24 μM).
Molecular docking studies have revealed that, overall, the inhibitory activity of phenols 
depends on two parameters: (i) hydrogen bonding capacity of the OH groups of the phenols 
with the side chains of amino acids such as Asp197 and Glu233, and (ii) planarity of aromatic 
rings to form an efficient conjugated π-π system with the indole Trp59 of the active site [20].
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(+) Hopeaphenol and (−) hopeaphenol oligomer (tetramer) of resveratrol isolated from 
Ampelocissus indica (L.) and Vateria indica Linn., respectively, displayed IC50 values of 21.21 ± 0.987 and 9.47 ± 0.967 mM in an α-glucosidase inhibitory assay [21], which were 
higher than the standard acarbose (IC50 81.3 ± 1.10). The compounds showed a concentration-
dependent inhibition of both α-glucosidase and α-amylase enzymes. Further, the study also 
indicated the positive effect of hopeaphenols as antiglycating agents, with IC50 values of 81.9 ± 1.176 and 50.96 ± 0.897, respectively, for (+) and (−) isomers which again were less than 
the ascorbic acid standard (IC50 158.23 ± 0.718). The results indicated that the hopeaphenols can be a promising natural compound in diabetic management [21]. The effect of glucose 
uptake performed by 2-NBDG in L6 rat skeletal muscle cells using flow cytometry (BD FACS 
Aria II, USA) showed potent glucose uptake by (+) and (−) hopeaphenol of 31 and 26.4%, 
respectively [21].
Few reports exist on the in-vivo studies of stilbenoids other than resveratrol. Among them is 
the effect of pterostilbene, which improves glycemic control in insulin-resistant obese rats by 
increasing hepatic glucokinase activity and increasing skeletal muscle glucose uptake [22]. 
In vitro studies also indicate that pterostilbene protected pancreatic beta cells against oxida-
tive stress and apoptosis [23]. Antihyperglycemic properties of pterostilbene along with other 
phenolic constituents of Pterocarpus marsupium have been reported [24, 25], whereas pterostil-
bene has been shown to be beneficial in animal models of diabetes and metabolic disorders. 
Further, the study by Lam et al. also revealed that pentahydroxystilbene (3,3′,4,4′,5′-pentahy-
droxy-trans-stilbene) possesses significant effect in reducing the postprandial blood glucose 
level of sucrose-challenged normal wistar rats [26].
2.3. Clinical studies on RSV on diabetic
Although numerous data exist on the beneficial outcomes of resveratrol in diabetic animals 
and in vitro, there are limited studies that have specifically investigated the antidiabetic effects 
of resveratrol in humans. Further, because of not only a limited number of clinical surveys, 
but also limited sample size and conflicting data, the use of resveratrol as an effective antidia-
betic agent has been delayed [27]. Few of the reported clinical trial data are discussed below.
Glycated hemoglobin (HbA1c) levels reflect glycemic control and can, consequently, be 
employed as a predictor of the microvascular and macrovascular complications associated 
with type 2 diabetes. HbA1c levels seem to be determined by postprandial hyperglycemia. 
Bhatt and colleagues demonstrated that resveratrol (250 mg/day for 3 months) administered 
along with glibenclamide and/or metformin demonstrated improvement in glycaemic param-
eters in diabetic patients as compared to metformin or glibenclamide alone [28]. The study 
reported improvement in HbA1c, systolic blood pressure, and total cholesterol in patients 
with type 2 DM treated with resveratrol combined with the oral hypoglycemic agents. 
Recently, Movahed and colleagues also reported [29] that 1 g/day of resveratrol supplementa-
tion for 45 days notably reduced fasting blood glucose, HbA1c, insulin, and systolic blood 
pressure. Brasnyó and colleagues [30] reported an improvement in insulin sensitivity in type 
2 diabetic patients after treatment with a much lower dose of resveratrol (5 mg twice daily) for 
4 weeks. The study showed that resveratrol did not cause any changes in a glucose-dependent 
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insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) levels in diabetes 
patients. However, they did show that resveratrol significantly decreased insulin resistance 
and blood glucose and delayed glucose peaks after meals. In the study, resveratrol treatment 
was shown to significantly decrease HbA1c, systolic blood pressure, and total cholesterol. 
A decrease in oxidative stress assessed by measuring urinary ortho-tyrosine excretion, a bio 
marker of oxidative stress, was also reported. Nevertheless, the authors found no evidence 
that resveratrol influenced homeostasis model of assessment of β-cell function (HOMA-β) and 
therefore suggested that the mechanism of antidiabetic effects might be referable to a reduc-
tion in oxidative stress and a more-efficient insulin signaling. Resveratrol activated the Akt 
insulin signaling pathway by increasing the phosphoAkt:Akt ratio in platelets.
Most significant notice from the above two studies is the extra security of resveratrol as com-
pared to available standard antidiabetic medication [31].
In contrast, in a randomized control trial by Thazhath et al., 500 mg of resveratrol was admin-
istration twice daily for 5 weeks in diet-controlled type 2 diabetes. The study revealed no 
significant improvement in glycemic control [32]. They studied two incretin hormones that 
affect postprandial hyperglycemia: glucose-dependent insulinotropic polypeptide (GIP) and 
glucagon-like peptide 1 (GLP-1) from the bowel. In healthy people, both hormones stimu-
late insulin, but in type 2 patients, only GLP-1 can act to stimulate insulin. GLP-1 can also 
suppress glucagon secretion and energy intake and slow gastric emptying, thereby targeting 
postprandial hyperglycemia. In rodent models, resveratrol has been shown to upregulate 
GLP-1 and lower glycemia, but Thazhath et al. found that in human patients, there was no 
difference between the GLP-1 secretion, fasting glucose level, postprandial glucose level, 
HbA1c, gastric emptying, body weight, or energy intake in the resveratrol-treated versus the 
placebo group. As such, resveratrol’s efficacy in improving glycemic control is indeterminate. 
Similarly, resveratrol treatment for 6 months did not improve metabolic parameters in type 2 
diabetic patients [33].
Crandall et al. studied older adults with impaired glucose tolerance (IGT), a major risk factor 
for diabetes as well as cardiovascular disease. They establish that although fasting plasma 
glucose was unchanged with low dose of resveratrol treatment, peak postmeal glucose and 
3-h glucose declined. Further postmeal insulin decreased and insulin sensitivity imporved. 
Thus, established resveratrol as a promising therapy for insulin resistance [34].
A meta-analysis was carried out by Liu et al. in 2014 [35] and more recently by Zhu et al. in 
2017 [36] with the aim of qualitatively comparing the published data on effect of resveratrol 
on plasma glucose levels, glycated hemoglobin (HbA1c), and insulin sensitivity. A fixed-effect 
model analysis was carried out to pool the data, nine studies with 283 participants in case by 
study of Zhu et al. and 388 participants of 11 eligible studies in case of Liu et al. The sample 
size of studies varied from 8 to 66 participants, with resveratrol dose ranging from 8 mg/d 
to 3000 mg/d and with duration of intervention differing from 2 weeks to 12 months. Both 
meta-analysis studies revealed that resveratrol was able to reduce the fasting plasma glucose 
levels only at high concentrations (1 g/day) as compared with placebo/control in patients 
with T2DM. Resveratrol was unable to reduce the plasma glucose levels at low concentra-
tions. These studies also revealed that compared to placebo group, the patients who received 
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resveratrol supplement also showed low insulin levels. Further resveratrol was also effective 
in reducing the systolic and diastolic blood pressures. However, no significant difference was 
observed in LDL and HDL levels.
On the other hand, effect of pterostilbene on human type 2 diabetes is yet to be researched. 
Administration of blueberry (Vaccinium myrtillus) and sea buckthorn (Hippophae rhamnoides) 
extract for children with type 1 diabetes for 2 months elicited a reduction in HBA1c levels 
and an increase in SOD and glutathione peroxidase levels [37]. Since pterostilbene has been 
isolated from Vaccinium myrtillus [38], this effect may be ascribable to the presence of pteros-
tilbene alongside other bioactive compounds in the excerpt.
Some beneficial effects have also been reported in resveratrol treatment in nondiabetic 
humans. In obese subjects, Timmers and colleagues [39] reported significant improvement 
in the metabolic profile and general health after resveratrol supplementation for 30 days, 
thereby describing resveratrol as a calorie restriction mimetic. Resveratrol showed benefi-
cial effects on glucose homeostasis and insulin sensitivity, reduced intrahepatic lipid (IHL) 
content and expression of inflammatory genes and improved mitochondrial efficiency. These 
effects may be linked with the activation of AMPK and increased SIRT1 and PGC-1α protein 
content in the muscle [39].
3. Way forward in clinical utility of resveratrol
One of the major challenges surrounding the clinical utility of resveratrol is achieving its sta-
bility and adequate bioavailability at tolerable doses—a common issue in translating promis-
ing findings from cell culture and animal models into clinical efficacious drugs. Recent clinical 
trials proved that resveratrol is well tolerated and pharmacologically safe at doses up to 5 g/
day. However, the data on toxicity of resveratrol in long-term experiments are scarce.
Low solubility of resveratrol in water (<0.05 mg/ml), caused by its chemical structure, affects 
its absorption. Its reported oral bioavailability values range from 20 to 29.8%. After intrave-
nous administration, resveratrol exhibited a very short half-life of 14 min due to rapid metab-
olism. This poor bioavailability can be ascribed to the rapid conjugation of trans-resveratrol to 
glucuronic acid and sulfates, producing glucuronides and sulfate conjugates that accumulate 
in plasma and urine.
In detail, resveratrol is absorbed in a relatively high rate through the small intestine either via 
passive diffusion due to its nonpolar character or through active diffusion across the intestinal 
epithelium via cell ATP-dependent binding cassette transporters. Inside the enterocytes of 
the small intestine and hepatocytes of the liver, the glucuronide and sulfate conjugation of 
trans-resveratrol to the major metabolites are extensive. This conjugation to sulfates and gluc-
uronides increases resveratrol’s aqueous solubility, reduces flux across membranes, prevent-
ing nonpolar molecules from interacting with essential macromolecules, and allows excretion 
by the kidneys via urine. The extensive metabolism to glucuronide and sulfate conjugates 
during absorption is well described and decreases circulating levels of free trans-resveratrol. 
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Thus, metabolism of resveratrol ultimately results in relatively small amounts of free trans-
resveratrol in the plasma to be delivered to other tissues. Strategies to increase bioavailability 
from oral delivery of resveratrol are generally focused on increasing the rate of resveratrol 
absorption into the enterocytes and decreasing intracellular metabolism [40]. Further, the 
photostability of the resveratrol itself must also be considered when developing formula-
tions, as resveratrol is sensitive to both heat and UV light. New approaches to increase the 
bioavailability of resveratrol can help to actualize its potentials as a therapeutic agent in DM 
and related complications.
Different approaches have been utilized by various researchers to increase the stability and 
bioavailability, some of which are discussed below.
3.1. Co-administration of resveratrol with other phenolic compounds
One simple approach to enhance bioavailability has been the consumption of resveratrol in 
combination with other phenolic compounds that play as the substrate for enzymes involved 
in resveratrol metabolism; such compounds which have demonstrated the positive effects 
are piperine, quercetin, etc. [41]. Combined effect of resveratrol along with curcumins was 
evaluated by Rouse et al. on animal models and human islet cell lines. Beneficial effects were 
demonstrated on insulin secretion by these naturally occurring polyphenols. However, the 
study revealed that the combination of resveratrol along with curcuminoids either did not 
yield any additional benefits or reduced the beneficial effects observed with the individual 
treatments. It would be noteworthy to test the combined effect of these two well-studied 
compounds on human models along with cinnamon and another known natural compound 
effective for diabetics. Further, clinical data are available on co-administration of resveratrol 
with various food and beverage, which contain subsequent amounts of other polyphenols 
such as grape juice, etc.; unfortunately, neither of these studies included a control condition 
to determine whether food or beverages enhanced or impaired bioavailability compared to 
resveratrol itself [41]. Due to 3-hydroxyl groups, resveratrol rapidly undergoes glucuronida-
tion or sulphation. The presence of two methoxy groups in the pterostilbene structure makes 
it more lipophilic and thus more bioavailable and also more metabolically stable because it 
has only one free hydroxyl group available for glucuronidation or sulphation. However, the 
data also reveal that more the free hydrozyl groups, it shows better activity in in-vitro assays. 
Furthermore, administration of pterostilbene in a clinical trial at a dose of 125 mg twice daily 
for 6–8 weeks was found to be safe and did not evoke any remarkable adverse reactions. Still, 
there are no clinical studies on the antidiabetic effect of pterostilbene on diabetic patients and 
its co-treatment with resveratrol.
3.2. Prodrugs and resveratrol formulations to increase the stability and 
bioavailability
Another approach to increase the absorption of resveratrol in the gastrointestinal tract is 
improving the material properties of resveratrol used in the oral dosage, given the rapid 
metabolism of resveratrol. This is the basis for SRT501, the patented formulation of micronized 
oral version of resveratrol that may have higher bioavailability. In this process, resveratrol is 
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microionized to particle sizes <5 μm, mixed with flavorings, colorings, and emulsifying agents 
such as docusate sodium and mixed with water for ingestion. The small particle size with the 
emulsifiers in solution theoretically increases surface area for intestinal absorption while also 
improving suspension properties [42].
Another approach to maximize the bioavailability of free trans-resveratrol is to develop res-
veratrol prodrugs, which could be used to improve the anti-diabetic efficacy of resveratrol. 
Assuming that maximizing free trans-resveratrol is the primary goal, resveratrol prodrug 
generates in vivo resveratrol through enzymatic reactions. Some of these technologies have 
been investigated in animal studies with no report in humans. Metabolism of prodrugs into 
resveratrol in tissues of interest can maximize tissue concentration and can be beneficial in the 
treatment of tissue specific complications in diabetic patients. Targeted delivery of resveratrol 
prodrugs into tissues of interest via delivery systems such as liposome-mediated delivery or 
nanotechnological approaches may result in the improved therapeutic effect. Also, intrave-
nous injection as an option to the traditional oral route of administration of resveratrol may 
bypass gastrointestinal absorption, conjugation, and hepatic metabolism, therefore resulting 
in increased bioavailability and improved results in diabetic patients.
3.3. Nanotechnological approaches to enhance the stability and bioavailability of 
resveratrol
A routine of recent surveys have concentrated on applying nanotechnology to improve 
the bioavailability of resveratrol and have generally demonstrated improved stability and 
bioavailability with minimal side effects compared to oral dosing. Nanoformulations can 
improve resveratrol’s solubility and transport across the plasma membrane and therefore 
enhance its effects within cells.
The nanoencapsulation methods include polylactic coglycolic acid nanoparticles [43, 44], 
carboxymethyl chitosan nanoparticles [45], solid lipid nanoparticles [46], and cyclodextrin 
nanoparticles [47]. Studies revealed sustained release profiles, which enhanced plasma bio-
availability compared to free resveratrol. Nanoencapsulation was also effective in improving 
the solubility and stability of resveratrol. All the same, no clinical or paraclinical studies have 
been done to determine the efficacy of resveratrol nanovectors against antidiabetic potential.
Nanovectors delivering resveratrol have been described by Singh and Pai that drew a sus-
tained release of trans-resveratrol from orally administered polylactic-co-glycolic acid 
nanoparticles (drug encapsulation efficiency more than 78%, with a molecule size of about 
170 NM) [43]. The same authors encapsulated resveratrol in Eudragit RL 100 nanoparticles 
with a drug incorporation efficiency of 84% and the average size of 180 nm. In vivo studies in a 
rat model showed prolonged plasma levels up to 16 h, in comparison with the free drug being 
cleared within 6 h [44]. Zu et al. developed carboxymethyl chitosan nanoparticles as a carrier 
for resveratrol [45]. These nanoparticles (155 nm-sized, with an encapsulation efficiency of 
44%) improved the solubility of resveratrol, thereby greatly affecting the antioxidant activ-
ity of the drug. Additionally, resveratrol-loaded solid lipid nanoparticles were synthesized 
with a controlled release profile, due to an initial burst release of 40% caused by the active 
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principle associated with the particle shell and a subsequent prolonged release of the drug 
located in the lipid matrix. In this system, the efficiency of the cellular uptake depended on 
the molecular interactions with the biological membrane organization, lipid rafts, and the 
actin cytoskeleton invaginations for the receptor-mediated entrance [48]. Resveratrol-loaded 
solid lipid nanoparticles have been also prepared by Pandita et al. with a drug incorporation 
efficiency of 89% and an average diameter of 134 nm [46]. This drug delivery system showed 
prolonged release in vitro up to 120 h in a Wistar rat model, enhancing plasma bioavailability 
compared to a free drug suspension. Finally, cyclodextrins-resveratrol complexes have been 
used to increase the concentration of polyphenol in aqueous solution while maintaining its 
biological activity. For example, spherical cyclodextrin-based nanosponges showed increas-
ing solubility and stability, together with good drug encapsulation efficiency, compared to 
free resveratrol [48].
4. Conclusion
There is a large body of evidence indicating resveratrol as an antidiabetic agent. Numerous 
studies have demonstrated that resveratrol can prevent, attenuate, or reverse diabetic dys-
function through diverse mechanisms and multiple molecular targets, which lead to pleio-
tropic therapeutic action in the whole organism. The exerted effects include inhibition of 
carbohydrate hydrolyzing enzymes (α-amylase and α-glucosidase) resulting in improved 
glycemic control, antioxidant properties, and antiinflammatory properties, which ultimately 
ameliorates diabetes and its complications. Resveratrol enhances insulin sensitivity and 
decreases insulin resistance, by changes in expression and activity of phosphodiesterases, 
kinases, AMPK, and SIRT1 in different tissues, which ultimately leads to protection of pan-
creatic β-cells from deterioration.
Despite widespread use of resveratrol as a nutritional supplement and the fact that animal 
models have provided a strong case for resveratrol as an antidiabetic agent, however, due 
to limited number of well-designed human clinical trials and various other limitations, this 
compound is still under investigation as an antidiabetic drug. The poor stability and bio-
availability of resveratrol in humans have been a major concern for translating basic science 
findings into clinical utility [49].
From the 11 human clinical trial data available on effect of resveratrol as antidiabetic agent, 
all studies have shown positive effect of resveratrol in reducing the fasting plasma glucose 
level at higher concentration. But still there remain many discrepancies such as on the Hb1AC 
levels. The origins of these discrepancies are not definitively known but may be due to differ-
ent quantification techniques (e.g., HPLC vs. MS/MS, etc.), different formulations and dosing 
protocols, and differing sample size, dosage duration, and effects of other drugs/materials 
used in combination with resveratrol. In addition, inter-bioavailability of resveratrol can 
vary from person to person, which may cause inconsistent physiological responses between 
individuals and limited clinical applicability. Thus, further well-defined clinical trials should 
exploit the efficacy of resveratrol itself or when used in combination with other antidiabetic 
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drugs (e.g., metformin, etc.) or with other known antidiabetic natural products (curcumins, 
cinamaldedhye, etc.) as a potential pharmaceutical intervention.
A number of approaches have been developed to improve the stability and bioavailability 
of resveratrol, including consumption with various foods containing multiple polyphenols 
and micronized powders, combining it with additional phytochemicals, controlled release 
devices, and nanotechnological formulations. Animal studies demonstrate that these 
advanced formulations could improve tolerability in humans while also increasing its bio-
availability; nonetheless, these nanotechnological and other advanced approaches are yet to 
be attempted in humans [41]. A combinational approach, as well as improved formulations of 
resveratrol, may help to overcome the challenge of maintaining an effective concentration at 
the site of action for an appropriate period, which needs to be confirmed by human studies.
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